Wayde McMillan Elected to Hologic Board of Directors




Wayde McMillan Elected to Hologic Board of Directors

MARLBOROUGH, Mass.–(BUSINESS WIRE)–$HOLX #governance–Hologic, Inc. (Nasdaq: HOLX) announced today that Wayde McMillan has been elected to the Company’s Board of Directors, effective April 4, 2025. Mr. McMillan was also appointed to the Audit and Finance Committee effective April 4, 2025.

Mr. McMillan has served as the Chief Financial Officer of Solventum Corporation, a carve-out health care company of 3M Company, since 2024 after serving as the Chief Financial Officer of 3M Company’s Health Care Business Group since November 2023. Previously, Mr. McMillan served as Executive Vice President, Chief Financial Officer and Treasurer of Insulet Corporation, a medical device company, from March 2019 to November 2023. From January 2015 to February 2019, he was Chief Financial Officer and Vice President of Finance of the Minimally Invasive Therapies Group at Medtronic plc, a medical device company. From November 2006 to January 2015, prior to Medtronic’s acquisition of Covidien plc, a medical device company, Mr. McMillan held a variety of leadership positions at Covidien. Mr. McMillan started his career in accounting, audit, financial analysis and investor relations positions at various institutions.

“We’re thrilled to welcome Wayde to Hologic’s Board of Directors,” said Steve MacMillan, Hologic’s Chairman, President and Chief Executive Officer. “His extensive financial expertise and deep understanding of the med-tech industry will be great complements to our current Board.”

Mr. McMillan earned his Bachelor of Science degree in Business Administration from Merrimack College and an MBA from Bentley University’s McCallum Graduate School of Business.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Forward Looking Statements

This press release contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions, and statements regarding the Company’s Board of Directors. These forward-looking statements are based on assumptions made by the Company as of this date and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. These risks include, but are not limited to, the risk that the Company may not be able to attract and retain qualified Board members or executives. These risks are not exhaustive. Other factors that could adversely affect the Company’s business and prospects are described in the filings made by the Company with the SEC. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented here to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

SOURCE: Hologic, Inc.

Contacts

Michael Watts
Corporate Vice President, Investor Relations

Michael.Watts@hologic.com
(858) 410-8514

Bridget Perry
Senior Director, Corporate Communications

Bridget.Perry@hologic.com
(508) 263-8654

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System




Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

• Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets

• Sangamo to receive an $18 million upfront license fee and is eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales

RICHMOND, Calif.–(BUSINESS WIRE)–Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license agreement with Eli Lilly and Company (“Lilly”), allowing Lilly to leverage Sangamo’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, which has demonstrated potent blood-brain barrier penetration and neuronal transduction in nonhuman primates. The agreement grants Lilly a worldwide exclusive license to utilize the STAC-BBB capsid for one initial target, with the right to add up to four additional targets after paying additional licensed target fees, to deliver their intravenously administered genomic medicines to treat certain diseases of the central nervous system.

“We believe STAC-BBB, our industry-leading intravenously delivered AAV capsid, has the potential to play an important role in the treatment landscape by addressing longstanding challenges associated with delivering therapies to the central nervous system,” said Sandy Macrae, Chief Executive Officer of Sangamo. “We are pleased to be sharing STAC-BBB with Lilly to advance potential treatments for neurological diseases with significant unmet medical needs. This marks the third agreement with a pharmaceutical company since we announced the discovery of STAC-BBB in March 2024 and demonstrates the continued industry interest in our capsid delivery technology.”

Under the terms of the agreement, Sangamo is responsible for completing a technology transfer related to the STAC-BBB capsid. Lilly is responsible for all research, preclinical and clinical development, regulatory interactions, manufacturing, and global commercialization of any resulting gene therapy products. Sangamo will receive an $18 million upfront license fee from Lilly and is eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments across the five potential neurology disease targets, as well as tiered royalties on potential net sales of such products, subject to certain specified reductions.

About Sangamo Therapeutics

Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo’s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter/X.

Forward Looking Statements

This press release contains forward-looking statements based on Sangamo’s current expectations. These forward-looking statements include, without limitation, statements relating to the potential for Lilly to develop genomic medicines to treat neurodegenerative diseases by leveraging Sangamo’s capsid delivery capabilities, the potential for STAC-BBB to play an important role in the treatment landscape and address challenges in delivering therapeutics to the central nervous system, the potential of Sangamo’s capsids to deliver therapies treating neurological diseases, the potential for Lilly to expand its license to include additional targets and to perform research, preclinical and clinical development, manufacturing and global commercialization of licensed gene therapy products for each licensed target, expectations concerning Sangamo’s receipt of an upfront license fee, the potential for Sangamo to receive additional licensed target fees, milestone payments, and royalties, and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the research and development process, including the results of preclinical studies and clinical trials; the regulatory approval process for product candidates; the potential for technological developments that obviate technologies used by Sangamo and its partners; the potential discontinuation of industry interest in Sangamo’s capsid delivery technology; any breach or termination of the Lilly agreement; and the potential for Sangamo to fail to realize its expected benefits from the Lilly agreement; Sangamo’s inability to secure additional collaboration partners; and Sangamo’s need for substantial additional funding to operate as a going concern. There can be no assurance that Sangamo will earn any milestone or royalty payments under the Lilly agreement or that Lilly will obtain regulatory approvals for product candidates arising from this agreement. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo’s and Lilly’s operations and businesses. Sangamo’s risks and uncertainties are described more fully in Sangamo’s Securities and Exchange Commission, or SEC, filings and reports, including in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC, and future filings and reports that Sangamo makes from time to time with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

Contacts

Sangamo Contact
Investor Relations & Media Inquiries

Louise Wilkie

ir@sangamo.com
media@sangamo.com

Scale Bio Joins Chan Zuckerberg Initiative’s Billion Cells Project, Accelerating Single Cell Research at Unprecedented Scale




Scale Bio Joins Chan Zuckerberg Initiative’s Billion Cells Project, Accelerating Single Cell Research at Unprecedented Scale

Scale Bio’s QuantumScale Single Cell RNA Kits Are Now Available for Order to Commercial and Academic Customers, Enabling the Analysis of Millions of Cells in a Single Workflow

SAN DIEGO–(BUSINESS WIRE)–#CZBiohubNY–Scale Biosciences, Inc. (Scale Bio), a leader in highly scalable single cell technologies, today announced its participation in the Chan Zuckerberg Initiative’s (CZI) Billion Cells Project at the Chan Zuckerberg Biohub New York Affiliate Symposium. Scale Bio joins technology partners 10x Genomics and Ultima Genomics in this landmark effort to generate an unprecedented one billion cell dataset to fuel rapid progress in cell biology through AI model development. This collaboration represents a significant expansion of the data generation capabilities for the Billion Cells Project.

Scale Bio is a demonstrated leader in advancing large-scale single cell studies, having leveraged its QuantumScale technology in its “100 Million Cell Challenge,” supported by CZI, Ultima Genomics, NVIDIA, and BioTuring, which helped lay important groundwork for the broader Billion Cells Project. The integration of Scale Bio’s technology with the Billion Cells Project will further accelerate the generation of high-quality, diverse cellular data to fuel advances in biological understanding.

“At Scale Bio, we are focused on accelerating scientific progress through the power of scale to improve human health. For too long, technological limitations have constrained what’s possible in single cell research,” said Giovanna Prout, President and CEO at Scale Bio. “With our QuantumScale and ScalePlex technologies, we’ve reimagined single cell analysis to drive unprecedented scalability, enabling researchers to conduct experiments previously considered infeasible, overly cumbersome, or too expensive. We are proud to collaborate again with CZI and participating researchers on the Billion Cells Project to push the boundaries of single cell omics, helping to generate data across diverse biological models at the scale needed to power new discoveries and develop impactful AI models. We’re excited to see our technologies contribute to such a monumental initiative.”

“Scale Bio will be a valuable partner to help us achieve our grand scientific challenge of building an AI-based virtual cell model to predict and understand cellular behavior,” said Jonah Cool, PhD, Senior Science Program Officer for Cell Science at CZI. “This collaboration will allow researchers to answer specific biological questions about cells and derive high-quality data with unprecedented scale and accessibility. We hope this partnership with Scale Bio is just the beginning of how innovative technologies can remove barriers to data generation, enabling researchers to build more comprehensive AI models that could provide insights into health and disease.”

Scale Bio’s QuantumScale Single Cell RNA kits, which were made available early to 100 Million Cell Challenge winners, are now commercially available in five configurations to academic and commercial customers around the world. The technology is a dramatic improvement over existing solutions, as it can capture and process up to 4 million cells in one short workflow without specialized partitioning instrumentation. Additionally, leveraging ScalePlex technology, researchers can multiplex up to 9,216 samples or conditions per run, making it uniquely suited for large-scale projects.

“With support from CZI and in partnership with interlocking efforts across HuBMAP and the Human Cell Atlas, we’re working to build a comprehensive cellular map of diseases that affect the inhalation interface—from the oral cavity through the upper airway and into the lung,” said Kevin Matthew Byrd, DDS, PhD, Researcher at Virginia Commonwealth University and recipient of a 100 Million Cell Challenge grant. “Chronic conditions like sarcoidosis and Sjögren’s disease impact this entire cul-de-sac of breathing. Scale Bio’s QuantumScale technology allows us to map millions of cells across these connected niches, uncovering shared mechanisms and opening the door to new diagnostic and therapeutic insights.”

Large-scale single cell analysis projects, such as the CZI Billion Cells Project, are critical to building a comprehensive understanding of cellular diversity. These initiatives accelerate understanding of cellular behavior and gene function while fueling the development of AI models that reflect diverse biology. Once completed, this single cell dataset will bring critical new data and resolution to multiple domains of biology that need comprehensive resources, enabling researchers to train AI models and make transformative discoveries across precision medicine and functional genomics.

For more information about the QuantumScale Single Cell RNA kits, visit scale.bio/single cell-rna-sequencing-kit/.

About Scale Bio

Scale Biosciences, Inc. (Scale Bio) is redefining single cell analysis by providing the most scalable omics tools to researchers worldwide, helping to advance the field of single cell omics and to accelerate discoveries in human health and disease. The company’s innovative QuantumScale and ScalePlex technologies enable unprecedented throughput and multiplexing capabilities, allowing researchers to conduct single cell experiments at scales previously unimaginable. For more information, visit scale.bio.

About the Chan Zuckerberg Initiative

The Chan Zuckerberg Initiative was founded in 2015 to help solve some of society’s toughest challenges — from eradicating disease and improving education, to addressing the needs of our local communities. Our mission is to build a better future for everyone. For more information, please visit chanzuckerberg.com.

Contacts

Media Contact:


For Scale Bio:

Gwen Gordon

gwen@gwengordonpr.com

We Row For William: 157 Miles, One Nonstop Journey of Hope




We Row For William: 157 Miles, One Nonstop Journey of Hope

Father and Crew to Row 157 Miles Continuously to Fund Lifesaving Gene Therapy for His Son

MEDFORD, Ore.–(BUSINESS WIRE)–On April 25, Joe Jackson and a dedicated crew of men including Jeremy Leever and Shaun Olson will embark on an extraordinary nonstop, overnight rowing journey covering 157 miles of the Rogue River to raise awareness and critical funds for his son, William Jackson, who is battling Duchenne muscular dystrophy (DMD).

What typically takes 10 days, Joe and his crew will complete in a single, grueling push, symbolizing the urgency of finding a cure for this relentless disease. The Rogue River is one of the nation’s most famous whitewater.

Duchenne muscular dystrophy is a progressive, life-limiting genetic disorder that causes muscle degeneration and weakness. To save William and other boys like him, the Jackson family is urgently working to raise $2.2 million to complete development of a CRISPR-based gene therapy. This drug development effort is spearheaded by Cure Rare Disease, a nonprofit biotech pioneering genetic treatment for ultra-rare diseases.

Their first crucial milestone is $800,000 by May 1, a goal they can reach if all 157 miles of this journey are sponsored.

“This is a race against time,” said Joe Jackson. “Rowing 157 miles straight is nothing compared to what William faces every day. We’re doing this to give him and other boys like him a real chance at life.”

How to Get Involved: WeRowForWilliam.org

• Sponsor a Mile: Each mile sponsored brings William closer to his first fundraising goal.
• Donate: Every contribution supports the development of a life-saving gene therapy.
• Spread the Word: Share William’s story and help make an impact.

Every dollar raised will directly fund the development of a first-of-its-kind CRISPR-based gene therapy for William and others fighting Duchenne.

To sponsor a mile, donate, or learn more, visit WeRowForWilliam.org/raiselysite.com or contact Brittany Stineman at Brittany@curerd.org.

About Cure Rare Disease

The mission of Cure Rare Disease is to develop and fund life-saving genetic therapies for ultra-rare diseases, transforming the lives of patients previously deemed untreatable. By fostering strategic collaborations among top researchers, clinicians, policy experts, and donors, Cure Rare Disease brings hope and advances solutions for those awaiting a cure.

Contacts

Media Inquiries:
Brittany Stineman

Brittany@curerd.org
773-751-9010

Mark Farrah Associates Simplifies Analysis of the Medicare Advantage and Prescription Drug Plan Senior Markets




Mark Farrah Associates Simplifies Analysis of the Medicare Advantage and Prescription Drug Plan Senior Markets

MCMURRAY, Pa.–(BUSINESS WIRE)–Mark Farrah Associates’ (MFA), www.markfarrah.com, Medicare Business Online™ (MBO) product simplifies the analysis and tracking of Medicare Advantage (MA) and stand-alone Prescription Drug Plan (PDP) enrollment by health plan as released by the Centers for Medicare & Medicaid Services (CMS). MFA’s improved user interface includes easy-to-navigate tables with download to Excel functionality allowing for swift monitoring of competitive positions in the MA and stand-alone PDP senior markets. Data is organized at national, state, and county levels and is aggregated by parent, contract, and plan. Trend data for Medicare Eligibles and current enrollment for Original Medicare are also featured.

Click here for more information about Medicare Business Online™.

About Mark Farrah Associates (MFA)

MFA is a leading data aggregator and publisher providing health plan market data and analysis tools for the healthcare industry. Committed to simplifying analysis of health insurance business, our products include: Health Coverage Portal™, Medicare Business Online™, Medicare Benefits Analyzer™, Med Supp Market Data, County Health Coverage™, Health Plans USA™ and 5500 Employer Health Plus. Follow us on LinkedIn!

Also, for the latest insights about health plan enrollment trends and financial performance, visit the FREE MFA Healthcare Business Strategy Briefs on the MFA website.

Contacts

Mark Farrah Associates

Ann Marie Wolfe, amwolfe@markfarrah.com

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program




BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

SAN CARLOS, Calif.–(BUSINESS WIRE)–$ONC #BeiGene–BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer.

The Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302 trial (NCT04746924) based on its findings as part of a pre-planned futility analysis. The overall efficacy and safety data assessment suggested that the study was unlikely to meet the primary endpoint of overall survival. No new safety signals were observed. After thorough deliberation, the Company has made the decision to terminate the trial.

“We evaluate our clinical programs to focus our resources on the most promising clinically differentiated candidates while thoughtfully de-prioritizing others. Our commitment remains steadfast: to discover and develop innovative treatments that are more affordable and accessible to cancer patients worldwide,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “We thank the investigators, their patients, and support staff whose participation and dedication made this research possible.”

Results from this study will be shared at a later date to help advance science and the understanding of anti-TIGIT activity.

About BeiGene

BeiGene, which plans to change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 11,000 colleagues spans six continents. To learn more about BeiGene, please visit www.beigene.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the ability of results from the AdvanTIG-302 trial to help advance science and the understanding of anti-TIGIT activity; and BeiGene’s plans, commitments, aspirations, and goals under the heading “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

To access BeiGene media resources, please visit our News & Media site.

Contacts

Investor Contact
Liza Heapes

+1 857-302-5663

ir@beigene.com

Media Contact
Kyle Blankenship

+1 667-351-5176

media@beigene.com

IBSA celebrates 40 years of history: “Drugs in the best form” – a success story that combines innovation with a focus on people




IBSA celebrates 40 years of history: “Drugs in the best form” – a success story that combines innovation with a focus on people

In 1985, IBSA (Institut Biochimique SA) was a small company in Lugano on the brink of bankruptcy. Today, 40 years later, the company celebrates the anniversary of its acquisition by its current CEO and President, Arturo Licenziati, who has led the business with a key philosophy: “Drugs in the best form”.

LUGANO, Switzerland–(BUSINESS WIRE)–#IBSA–The year 2025 marks an important year for the IBSA Group (Institut Biochimique SA), which celebrates a double anniversary: 40 years of leadership by its CEO and President Arturo Licenziati, and 80 years since the creation of the IBSA name. These milestones coincide with another significant event: the 90^th birthday of President Licenziati, who today – April 3, 2025 – celebrates this major occasion.

To mark the company’s 40^th anniversary, IBSA has decided to grant all employees worldwide a day off on August 19, the date when Arturo Licenziati first stepped into IBSA.

“This is just a symbolic gesture to express my gratitude for the commitment, dedication and passion of our People, who are the driving force behind our growth. A growth that is not just about business, but also – and above all – about the ability to implement development and work models that place People at the centre of our philosophy and our activities”, said Licenziati.

Indeed, it was on August 19, 1985, that Licenziati took over the management of the Ticino-based company, founded in Lugano in 1945, redefining its vision and strategy. At that time, IBSA had just 40 employees and a turnover of 5 million Swiss francs. However, by the end of the 1980s – in just 5 years – the company had radically transformed, tripling its revenue.

The history of IBSA is the story of a company that evolved from a small pharmaceutical laboratory in the Swiss Canton Ticino into a multinational corporation. What many people saw as an impossible mission, President Licenziati embraced as a challenge to be won, with the aim of forging a new path, focused on innovation and the ability to respond to people’s actual needs.

“Small companies can only grow if they can adapt quickly to sectors that large pharmaceutical companies often overlook”, added Licenziati. “Over the years, we have transformed an idea –producing “drugs in the best form” – into a concrete and successful project, focusing on targeted research that meets the everyday needs of doctors and patients. We have always been a forward-looking company, ready to go beyond and willing to explore new, uncharted paths”.

Since the 1990s, IBSA has embarked on a global expansion, first in Europe and then worldwide. Today the company has 20 subsidiaries across Europe, China and the United States, and distributes its products in over 90 countries across 5 continents, with more than 2,300 employees between headquarters, subsidiaries and production sites.

Contacts

Chérine Gurtner, Senior Consultant

cherine.gurtner@furrerhugi.ch

Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors




Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors

• VVD-159642, Vividion’s fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Kα, a key signaling pathway implicated in solid tumor development and progression
• Preclinical data support clinical trials with a broad patient population, and may deliver increased efficacy in combination with other RAS/MAPK pathway inhibitors
• Approximately 20 percent of all cancers are driven by mutations of the RAS family of genes¹
• Vividion continues to advance the chemoproteomics technology platform with goal to unlock disease-causing, yet traditionally undruggable targets with precision small-molecule therapeutics

SAN DIEGO & BERLIN–(BUSINESS WIRE)–Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial evaluating VVD-159642, an investigational oral inhibitor designed to target RAS-driven cancers. Vividion is a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, utilizing innovative discovery technologies to unlock targets with strong disease-link, yet traditionally undruggable and develop small molecule precision therapeutics for devastating cancers and immune disorders.

The new Phase I study (NCT06804824) will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of VVD-159642 as a single agent and in combination with either sotorasib or trametinib in patients with advanced solid tumors.

“Despite being a major driver in approximately 20% of cancers, the RAS gene has proven exceptionally difficult to target with drugs, largely due to its essential role in the RAS-PI3Kα signaling pathway, which is vital for healthy cell function,” said Jenna Goldberg, M.D., Chief Medical Officer of Vividion. “VVD-159642 is designed and being studied to selectively prevent RAS activation of the PI3Kα pathway, thus blocking oncogenic signaling without disrupting normal cellular function. Preclinical studies of VVD-159642 give us confidence in its potential to inhibit tumor growth while avoiding the on-target toxicities that have limited prior attempts to drug this important target. In addition to providing a more tolerable alternative to current therapies, we believe that VVD-159642 has potential to treat a broad patient population, including in both RAS-mutant and HER2-overexpressed tumors, and may deliver increased efficacy in combination with other RAS/MAPK pathway inhibitors.”

“We’re excited to bring our fourth innovative oncology asset into the clinic, which not only represents continued validation of Vividion’s covalent-first chemoproteomics platform but also provides a potential new treatment option for patients with RAS-driven cancers,” said Aleksandra Rizo M.D., Ph.D., Chief Executive Officer of Vividion.

“The team at Vividion is rapidly advancing scientific innovations into clinical development that have the potential to address multiple devastating diseases not reachable by current therapies,” said Christian Rommel, Ph.D., Head of Research and Development at Bayer’s Pharmaceuticals Division. “The initiation of this clinical trial marks a significant step forward in leveraging Vividion’s innovative drug discovery approach to target a highly relevant signaling pathway and bring a potential new treatment option to people suffering from difficult-to-treat cancers.”

Vividion also has ongoing Phase I trials evaluating an oral KEAP1 activator in solid tumors and oral STAT3 inhibitor in solid and hematologic malignancies. The company is advancing multiple innovative drug discovery programs toward the clinic and has a rich pipeline of opportunities emerging in early discovery in the fields of oncology and immunology.

About Vividion

Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a clinical stage biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders. The company’s platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets. The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. For more information, please visit www.vividion.com.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Find more information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/bayer

aka                (2025-0057)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Reference:

1. Ian A. Prior et al “The Frequency of RAS Mutations in Cancer”. Cancer Res (2020) 80 (14): 2969–2974. Available at: https://aacrjournals.org/cancerres/article/80/14/2969/640657. Accessed: March 2025.

Contacts

Bayer Global Media Contact:

Derin Denham, phone +1 973 610 7324
Email: derin.denham@bayer.com

Contact for media inquiries Bayer U.S.:
Elaine Colon, phone +1 732 236 1587
Email: elaine.colon@bayer.com

Vividion Media Contact:
Laurie Sherman, phone +1 858 630 8246
Email: media@vividion.com

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum




Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum

MARSEILLE, France–(BUSINESS WIRE)–Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will present and host 1×1 meetings at the Stifel 2025 Virtual Targeted Oncology Forum being held on April 8 – 9, 2025.

The executive team will participate in a fireside chat scheduled on Wednesday, April 9, 2025, from 12:30 – 12:55 p.m. ET.

A live webcast and a replay of the presentation will be available on the Events page in the Investors section of Innate Pharma website.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET^® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).

Innate’s portfolio includes several ANKET^® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “expect” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Contacts

For additional information, please contact:
Investors
Innate Pharma
Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

Henry.wheeler@innate-pharma.fr

Media Relations
NewCap
Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

innate@newcap.eu

Sylvan Receives Investment from Novo Holdings to Drive Further Growth




Sylvan Receives Investment from Novo Holdings to Drive Further Growth

Transaction marks Novo Holdings’ largest investment in the planetary health space in Asia

BEIJING–(BUSINESS WIRE)–Novo Holdings, a leading global life science investor, and KKR, a leading global investment firm, today announced the signing of definitive agreements under which Novo Holdings will make a direct investment in Sylvan, a world-leading manufacturer of fungal biotechnology solutions (or the “Company”). KKR will remain the Company’s majority shareholder.

Novo Holdings’ investment in Sylvan marks its largest planetary health investment in Asia and its first in the fungal biotechnology sector, both of which are strategic priorities due to their growth prospects and potential for impact on planetary health.

The new capital will support Sylvan’s expansion by enabling increased production capacity, upgraded R&D infrastructure, and deeper penetration into high-growth markets, particularly in Asia. Sylvan will also benefit from Novo Holdings’ extensive network and sector expertise to further strengthen its position in the global mushroom spawn market and develop new high-impact bio-products, such as fungi-based materials, biopesticides, and nutritional supplements.

Founded in 1932, Sylvan is the world’s largest mushroom spawn and fungal biotechnology company and headquartered in China. The company seeks to harness the potential of fungal systems to create sustainable solutions to address global challenges in food, health, agriculture, and materials. Today, the Company operates multiple production facilities around the world and serves customers across 65 countries.

From spawning to cultivation, the modern mushroom sector offers significant sustainability benefits and circular economy value to planetary health. It requires minimal land and water compared to traditional agriculture and utilizes agricultural waste as raw materials to produce high-quality proteins. Sylvan views China as an important growth market, where the downstream mushroom cultivation sector has experienced strong industrialization transition tailwinds, which is driving greater demand for spawn and supporting the acceleration of agricultural modernization and rural economic growth across the country.

Jackie Qi, CEO of Sylvan, said, “Sylvan is delighted to welcome Novo Holdings as our latest investor and to have the continued support of KKR, who have been a terrific strategic partner in our value creation journey. With this latest milestone, we are in an excellent position to pursue our ambition to become a global leader in fungal biotechnology solutions across four unique markets: Food, Health, Agriculture, and Materials, and will look to leverage their global networks and expertise to take Sylvan to the next level of transformation.”

Amit Kakar, Managing Partner and Head of Asia, and Deepa Hingorani, Partner, Head of Planetary Health Asia, Novo Holdings, jointly added, “Sylvan represents a significant milestone for our global Planetary Health strategy and underscores our growing presence in Asia. As a leader in fungal biotechnology, Sylvan is well-positioned to deliver sustainable innovations that support food security, reduce chemical use, and build a circular bioeconomy. We look forward to collaborating with KKR to help Sylvan scale its impact, particularly across dynamic markets in Asia, and advance our shared vision for a healthier and more sustainable planet.”

Chris Sun, Partner and Head of China Private Equity, KKR, said, “We are pleased to welcome Novo Holdings given their significant expertise in life sciences and planetary health. KKR is aligned with Novo Holdings in our commitment to drive the creation of sustainable global solutions. We are proud of the tremendous progress Sylvan has achieved and believe this new strategic partnership will enable it to unlock even greater growth.”

Novo Holdings’ Planetary Health Investments team spans three continents (Europe, North America and Asia), and invests in areas where science and technology can deliver returns while tackling global challenges, including feeding a growing world population, fighting climate change and drought, or creating sustainable cities.

About Sylvan

Sylvan is a fungal biotechnology company, unlocking the incredible potential of the Earth’s ancient fungi. We believe these resilient fungi, having evolved over millions of years, hold the key to overcoming many of the problems our planet faces today and into the future. Our goal is simple: harness the power of fungi and create sustainable solutions to address global challenges in food, health, agriculture, and materials.

About Novo Holdings

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2024, Novo Holdings had total assets of €142 billion. www.novoholdings.dk

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

Contacts

Media Contact


For Sylvan

Melinda Kong

melinda.kong@sylvaninc.com

For Novo Holdings

Paul Ewing-Chow

pec@novo.dk

For KKR Asia Pacific

Wei Jun Ong

WeiJun.Ong@kkr.com